Navigation Links
Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis

Corporate Communications, (450)680-4572, lhebert@neurochem.com

Ticker Symbol: (Toronto:NRM.),(NASDAQ-NMS:NRMX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
2. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
3. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
4. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
5. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
6. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
9. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
11. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
Post Your Comments:
(Date:5/15/2008)...flects depth and breadth of, collaboration with i...or diverse forms of cancer ...R), the leading IV, bisphosphonate, on relapse rat...our oral sessions to feature RAD001, first oral on...first results of RECORD-1 study in renal cell ...
(Date:5/15/2008)...May 15 /- Cerenis,Therapeutics SA (Ce...veloping HDL-related compounds for the treatment o...ounced that it has completed a Phase I,clinical tr... candidates.,CER-002 is a peroxisome proliferator-...n development for the treatment of cardiovascular,...
(Date:5/15/2008)...iplatelet Therapy that, Combined, with Aspirin, Ca...Iscover and Aspirin, According to a New Report.../- Decision Resources, one of the,wor...aceutical and,healthcare issues, finds that Daiich... patient compared to Sanofi-Aventis/Bristol Myers ...
(Date:5/15/2008)... Omega 3 fatty acids bound to,phospholipids deserv...alternative and may have beneficial effect on impu...udy reveals. While several studies have reported,b...nch researchers have,hypothesized that Vectomega(R...control., These research findings have led to the...
Breaking Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Crdentia Announces Appointments of David Jenkins and Raymond Dunn to Board of Directors 16532 1Crdentia Announces Appointments of David Jenkins and Raymond Dunn to Board of Directors 16532 2Crdentia Announces Appointments of David Jenkins and Raymond Dunn to Board of Directors 16532 3Abaxis to Present at the SunTrust Robinson Humphreys 37th Annual Institutional Unconference 16530 1Abaxis to Present at the SunTrust Robinson Humphreys 37th Annual Institutional Unconference 16530 2Cardinal Health Awards 241 Million to Fund Patient Safety Initiatives 16528 1Cardinal Health Awards 241 Million to Fund Patient Safety Initiatives 16528 2Cardinal Health Awards 241 Million to Fund Patient Safety Initiatives 16528 3Cardinal Health Awards 241 Million to Fund Patient Safety Initiatives 16528 4Cardinal Health Awards 241 Million to Fund Patient Safety Initiatives 16528 5Cardinal Health Awards 241 Million to Fund Patient Safety Initiatives 16528 6Amnis Announces Release of Powerful New Image Data Analysis Software 4526 1Amnis Announces Release of Powerful New Image Data Analysis Software 4526 2
...ht Change Reported Unlike What Is Commonly Seen In...re-FirstCall/ -- Novo Nordisk,today announced resu...afety and efficacy of insulin Levemir(R) (insulin ...pe 2 diabetes were able,to adjust their own dosage...ugar, comparable to dosing adjusted by their prima...
...SINESS WIRE)--Jun 23, 2007 - Late breaking data,pr... 67th Annual,Scientific Sessions showed that, when...A(TM) (sitagliptin) in combination with,metformin ...generally well tolerated over 54 weeks in patients...vestigational studies,presented also showed that J...
Other Medicine Technology:New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 2New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 3New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 4New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 5Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 2Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 3Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 4Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 5Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 6Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 7Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 8Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 9Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 10Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 11Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 12Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 13Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 14Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 15Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 16Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 17Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 18Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 19Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 20Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 21Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 22Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 23Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 24Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 25Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 26Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 27Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 28Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 29Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 30Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 31Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 32
(Date:5/16/2008)...R, Minn., May 16 /PRNewswire-USNewswire/ -- This r...Mayo Clinic in conjunction with the,National Cance...udy being presented at the American Society of Cli..., may change treatment practice,in about 25 percen...or,proposed changes to the way colorectal cancers ...
(Date:5/16/2008)... Covers More than 500 Workers, WASHINGTON, May 16...cs,and emergency medical technicians in the Greate...have ratified their first-ever contract as,Teamste...s are now covered by a,strong contract that gives ...," said Teamsters General President Jim Hoffa., T...
(Date:5/16/2008)...rom an international, multicenter Phase III clinic...therapy everolimus (RAD001) significantly delays c...ey cancer whose disease had worsened on other trea...n attending physician at Memorial Sloan-Kettering ...gs on May 31 at the annual meeting of the American...
(Date:5/16/2008)...n) Declaring that Primary care medicine is in a p...dent of the American College of Physicians (ACP), ...oyers and consumers to issue a call for comprehens... internists and other primary care physicians. ,...y care medicine in the U.S., Dr. Dale and other pa...
Breaking Medicine News(10 mins):Health News:New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer 2Health News:Drug fends off kidney cancer progression 2Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2
...s reported that an 8-year decline in the smoking r... to its halt at 21% in the last 2 years//. Accord...ease Control and Prevention, a lack of drop in smo...e 2002 is represented by the plateaus in smoking p...
...s in Jaipur, flower therapy is becoming the most s...ople enhance their beauty are parlours// and clini...roblems or under eye dark circles, flower therapy ..."We get 7 to 10 customers every day," says Neerja,...
... in St.Hyacinthe, 65 km south east of Montreal h...d diarrhoea which is still to be contained// . 22 ... well have been affected. The infection has been ...ince July and is believed have been responsible fo...
...l that more than half the population in New South ...he 30,000 people who were interviewed// this year...lects that there is almost 10%increase in obesity ...s population survey also brings to light that most...
Other Medicine News:Health News:Drop in smoking rate stalls 2
Sundt Slim-Line Temporary Vessel Clips used for temporary vascular occlusion during intracranial surgical procedures. Non-magnetic, MP35N, MRI compatible, gold color. Bayonet.
Malis Needle Holders, bayonet, titanium. Working distance 2 1/2" (63 mm). Straight tip with width 0.6 mm.
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface.
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface.
Medicine Products: